a-Synuclein misfolding and aggregation is a hallmark in Parkinson's disease and in several other neurodegenerative diseases known as synucleinopathies. The toxic properties of a-synuclein are conserved from yeast to man, but the precise underpinnings of the cellular pathologies associated are still elusive, complicating the development of effective therapeutic strategies. Combining molecular genetics with target-based approaches, we established that glycation, an unavoidable age-associated post-translational modification, enhanced a-synuclein toxicity in vitro and in vivo, in Drosophila and in mice. Glycation affected primarily the N-terminal region of a-synuclein, reducing membrane binding, impaired the clearance of a-synuclein, and promoted the accumulation of toxic oligomers that impaired neuronal synaptic transmission. Strikingly, using glycation inhibitors, we demonstrated that normal clearance of a-synuclein was re-established, aggregation was reduced, and motor phenotypes in Drosophila were alleviated. Altogether, our study demonstrates glycation constitutes a novel drug target that can be explored in synucleinopathies as well as in other neurodegenerative conditions. Keywords: glycation; Parkinson's disease; neurodegeneration; alpha-synuclein Abbreviations: AGEs = advanced glycation end-products; CEL = N(epsilon)-(carboxyethyl)lysine; fEPSP = evoked field synaptic potential; iPSC = induced pluripotent stem cell; LTP = long term potentiation; LUHMES = Lund human mesencephalic cells; MGO = methylglyoxal; SUV = small unilamellar vesicle
Introduction
The molecular underpinnings of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease remain unclear, as genetics explains only a minor fraction of cases. Therefore, the study of non-genetic factors that may contribute to the development of neurodegenerative diseases is urgent. Neurodegenerative diseases are known to be associated with the misfolding and accumulation of various proteins. Parkinson's disease is a common disorder known for typical motor features that result from the loss of nigrostriatal dopaminergic neurons (DA), and for the accumulation of pathognomonic intraneuronal inclusions known as Lewy bodies and Lewy neurites. These inclusions are primarily composed of a-synuclein (Spillantini et al., 1998; Wales et al., 2013) , a protein also associated with other disorders known as synucleinopathies.
We and others have extensively exploited yeast cells expressing neurodegenerative disease-associated proteins to recapitulate important cellular pathologies, thereby accelerating our understanding of the molecular basis of these disorders Tenreiro and Outeiro, 2010) . Recently, we found that DJ-1, the product of the PARK7 gene, interacts with and protects against a-synuclein aggregation and toxicity in yeast and in mammalian cell models of Parkinson's disease (Zondler et al., 2014) . DJ-1 mutations cause autosomal recessive Parkinson's disease through a loss-of-function mechanism. Recently, this protein was shown to have both glyoxalase (Lee et al., 2012) and deglycase activities , suggesting glycation, an unavoidable age-associated process, might play a role in Parkinson's disease. In a previous unbiased genetic screen in yeast, we identified another component of the glyoxalase system (Glo4) as an enhancer of a-synuclein toxicity (Willingham et al., 2003) . In fact, glucose is readily metabolized generating reducing sugars that covalently react with proteins generating advanced glycation end-products (AGEs) that invariably impact on protein function (Vicente Miranda and Outeiro, 2010) .
Intriguingly, diabetes, a widespread condition of impaired glucose metabolism, has been established as an important risk factor for Parkinson's disease (Hu et al., 2007; Sun et al., 2012; Vicente Miranda et al., 2016a) . The levels of AGEs are increased in the brains of patients suffering from synucleinopathy (Dalfo et al., 2005) , and AGEs can be detected at the periphery of Lewy bodies (Castellani et al., 1996) . A similar staining pattern of AGEs was reported in early Lewy bodies in patients with Lewy body disease. This suggested that an excess of carbonyl compounds could play a role in the pathogenesis of Parkinson's disease (Munch et al., 2000) . However, it has been unclear whether AGEs are causally related to disease and whether a-synuclein is glycated. Here, we asked whether manipulation of the major component of the glyoxalase system (GLO1) would affect a-synuclein aggregation and toxicity. GLO1 constitutes a major line of defence against methylglyoxal (MGO), a dicarbonyl metabolite that is formed unavoidably via multiple catabolic processes (Reichard et al., 1986; Lyles and Chalmers, 1992; Richard, 1993; Thornalley et al., 1999; Baynes and Thorpe, 2000) . MGO glycates arginine and lysine residues. With the latter, MGO forms N(epsilon)-(carboxyethyl)lysine (CEL) (Ahmed et al., 1997) and the imidazolium crosslink, methylglyoxal-lysine dimer (MOLD) (Frye et al., 1998) . Glo1 activity depends on reduced forms of glutathione (GSH), to which MGO reversibly associates with, forming an MGO-GSH hemithioacetal (substrate of GLO1), and NADPH, respectively (Vander Jagt et al., 1992; Gomes et al., 2005) . Therefore, the catabolism of MGO leads to a decrease in the levels of these cofactors, which are also crucial for oxidative stress responses. Interestingly, in hyperglycaemia conditions and in diabetic patients, MGO is increased, leading to higher MGO-glycation levels (2-4-fold) (Yao and Brownlee, 2010; Bierhaus et al., 2012) . Notably, the brain's defences against glycation, such as GSH and GLO1, decrease with ageing (Chen et al., 1989; Kuhla et al., 2006) , and in the substantia nigra of Parkinson's disease patients (Pearce et al., 1997) , suggesting that MGO levels may increase with ageing and in Parkinson's disease. Altogether, determining the molecular mechanisms through which glycation alters proteostasis and contributes to synucleinopathies enables an important breakthrough that links ageing to neurodegeneration and uncovers novel therapeutic targets for intervention in synucleinopathies.
Materials and methods

MGO purification
MGO was produced as in Gomes et al. (2005) . Briefly, MGO was prepared by sulphuric acid hydrolysis of 1,1-dimethyl acetal. The resulting MGO was purified by fractional distillation under reduced pressure and nitrogen bleed. MGO was evaporated at $72 C and three fractions were obtained. The first fraction was discarded, as it contained MGO mixed with methanol. The second fraction was collected and stored at À80
C until further use.
a-Synuclein aggregation and toxicity in yeast
Saccharomyces cerevisiae strain BY4741 and mutant strains Áglo1 and Átpi (Euroscarf collection) were used. Cells were grown and transformed as in Vicente Miranda et al. (2013) . Briefly, a-synuclein and familial variants A30P, E46K and A53T were expressed using the p426 GPD vector after transformation into yeast cells using the lithium acetate method. Transformants were selected in Yeast Nitrogen Base complete media without uracil (YNB-U). D-Glucose treatment was performed challenging cells for 24 h with 4% D-glucose in media. Fluorescent micrographs were acquired with a Zeiss Axiovert 200M. Toxicity assays were performed as previously by spotting serial dilutions of yeast cells onto agar-YNB-U plates. Cell viability was assessed by counting colony-forming units (CFUs) after growth for 2 days at 30 C on YEP-glucose as previously described (Tenreiro et al., 2014b) .
H4 cells immunocytochemistry, immunoblotting and toxicity
H4 neuroglioma cells were maintained, grown and transfected with a-synuclein, an aggregation-prone variant of asynuclein (SynT) and synphilin-1 (Synph 1) as in Vicente Miranda et al. (2013) with FuGENE Õ 6 (Roche) using standard procedures. Twenty-four hours after SynT and Synph 1 co-transfection, cells seeded at 20 000 cells/cm 2 in 35 mm imaging dishes (Ibidi) or seeded at 30 000 cells/cm 2 in 10 cm, 6 cm, 6-well plates or 12-well plates (TPP) were treated with vehicle (H 2 O) or MGO (0.5 mM) for 16 h. Cells washed with phosphate-buffered saline (PBS) were fixed and permeabilized in 100% ice-cold methanol (À20 C, 10 min). Cells were incubated with blocking solution (1.5% normal goat serum in PBS) for 1 h at room temperature. Cells were incubated with the primary antibody anti-a-synuclein (Cell Signaling Technology, 2642) Sucrose gradient fractions were applied in a dot-blot system and immunoblotting performed according to standard procedures (Basso et al., 2013) . For immunoblotting, we used the following antibodies: anti aSyn (BD Transduction laboratories, S63320, 1:3000); anti-V5 (Santa Cruz, SC-83849-R, 1:1000); anti-LC3 (Nano Tools, 0260-100/LC3-2G6, 1:2000); anti-b-actin (Ambion, AM4302, 1:5000); and anti-GAPDH (Ambion, AM4300, 1:5000).
Cytotoxicity was measured using Caspase-3 or lactate dehydrogenase (LDH) kit (Clontech). Total protein lysates were obtained as in Vicente Miranda et al. (2013) .
a-Synuclein immunoprecipitation
H4 neuroglioma cells were transfected with a-synuclein or cotransfected with SynT and Synph 1. Twenty-four hours post-transfection, cells were challenged with PBS (Ctrl) or MGO (0.5 mM) for 16 h. Media was renewed and cells challenged for 6 h. Protein was extracted using immunoprecipitation (IP) buffer (150 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1% NP-40, 0.1% SDS and complete protease inhibitors). Protein extract (500 mg) was precleared in 10 ml of protein G beaded agarose resin (Invitrogen) for 1 h under nutation at 4 C. Protein supernatant was incubated with 2.4 mg of anti a-synuclein antibody (BD Transduction laboratories, S63320) and nutated at 4 C overnight. Beads were collected and washed 4Â in IP buffer. Samples were immunoblotted as previously indicated using anti-a-synuclein (C-20 Santa Cruz biotechnology, sc-7011-R, 1:1000) and anti-AGEs (Millipore, AB9890, 1:1000).
MGO measurement
MGO was extracted from yeast or H4 cells with HClO 4 3 M at 4 C for 10 min and stored at À80 C. After derivatization with 1,2-phenylenediamine 0.92 mM and solid-phase extraction of quinoxalines, MGO levels (as 2-methylquinoxaline) were determined by reverse phase HPLC on a Merck Hitachi system: pump L-2130; column oven L-2300; UV detector L-2400. Samples were separated on LiChroCART LiChrospher Õ RP-18 endcapped (5 mm, 250-4.6) with methanol/ammonium formate 20 mM pH3.4 (60/40) used as mobile phase (1 ml/min); 20 ml as injection volume; and detection at 320 nm. Dimethylquinoxaline, added prior to solid-phase extraction was used as internal standard. MGO was normalized to dimethylquinoxaline.
LUHMES cells
Proliferating LUHMES (Lund human mesencephalic) cells (a kind gift of Prof. M. Leist, University of Konstanz, Germany) were cultivated in LUHMES proliferation medium containing advanced DMEM/F12, 1% N2 supplement (Invitrogen), 2 mM L-glutamine (Gibco), and 40 ng/ml recombinant basic fibroblast growth factor (R&D Systems) on cell culture T75 and T175 flasks or multi-well plates (Nunc) precoated with 50 ng/ml poly-L-ornithine (PLO) and 1 mg/ml fibronectin (Sigma-Aldrich) at 37 C and 5% CO 2 . Differentiated LUHMES cells were generated by replacing proliferation medium by differentiation medium containing advanced DMEM/F12, 1% N2 supplement, 2 mM L-glutamine, 1 mM dibutyryl 3 0 ,5 0 -cyclic AMP, (Sigma-Aldrich), 1 mg/ml tetracycline, and 2 ng/ml recombinant human glial derived neurotrophic factor (R&D Systems). After 2 days, cells were seeded into PLO/fibronectin precoated multi-well plates.
Generation of stable expressing clonal LUHMES cells
Proliferating LUHMES cells were transduced by lentiviral delivery of a-synuclein-IRES-GFP (green fluorescent protein) or IRES-GFP constructs, a third-generation lentiviral system as described previously (Tiscornia et al., 2006) . Purified lentivirus encoding a-synuclein and GFP were kindly provided by Dr B. Winner (Interdisciplinary Center for Clinical Research, Nikolaus-Fiebiger Center for Molecular Medicine, Erlangen). Cloning of stably-expressing (GFP-positive) cells was performed by single cell colony culture using limited dilution (LUHMES cells).
MGO treatment of LUHMES cells
For MGO treatment, predifferentiated (Day 2) LUHMES cells were seeded into 96-well plates (0.75 Â 10 5 cells) or into 24-well plates (0.3 Â 10 6 cells) and incubated at 37 C, 5% CO 2 for 3 days. MGO stock was sterile filtered and prediluted 1:100 in sterile pure water. Predilution was again diluted in LUHMES differentiation medium. Cell culture medium was removed. MGO dilution (120 ml) was added at the indicated concentrations. Cells were then incubated at 37 C, 5% CO 2 until the measurement of toxicity.
LUHMES viability assay and immunocytochemistry
Cellular viability was determined by the conversion of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to formazan, measured by the absorbance (490 nm) of intracellular formazan using a 96-well plate reader according to the manufacturer's protocol (MTSassay, Promega). For immunocytochemistry, cells were cultured on 13 mm glass coverslips in 24-well plates as described above. Cells were fixed for 15-20 min with 4% paraformaldehyde at room temperature, washed three times in Tris-phosphate-buffered solution (TBS) and incubated in fish skin gelatin buffer (FSGB) containing 0.1% Triton TM X-100 for 20 min at room temperature. Primary antibodies (rat anti-a-synuclein, 15G7, 1:250; rabbit anti-Caspase 3a, 1:500, Cell Signaling Technology) were diluted in FSGB and applied overnight at 4 C. After washing, secondary antibodies (dk-anti-rt, rhodamine, 1:500, Dianova; dk-anti-rb, diluted in 300 ml/well FSGB) were added and the plate was incubated at room temperature for 1 h in the dark. After removing the secondary antibody and washing once with FSGB, DAPI (diluted in 500 ml/well FSGB) was added and again incubated at room temperature for 15 min. The coverslips were mounted with ProLong Õ Antifade. Images were acquired using a Zeiss ApoTome microscope.
Differentiation of patient-derived induced pluripotent stem cells
The neuronal lineage control and patient human-induced pluripotent stem cells (iPSCs) were isolated and characterized by The Parkinson's Institute (Byers et al., 2011; Mak et al., 2012) and made available through a joint BMBF-CIRM grant to T.M.J. (315050 AZ0101). An extensive comparative characterization between control and SNCA triplication is presented in Oliveira et al. (2015) . a-Synuclein knockdown (KD) in the triplication line was achieved with the transduction of a lentiviral shRNA using the pLKO.1 Puro vector containing the 5 0 ACCAAAGAGCAAGTGACAAAT-3 0 . Stage IV cells were cultivated and differentiated in two stages (Mak et al., 2012) : 10 days in DA1 medium (using 1 mM SAG) and 20 days in DA2 medium.
Cytotoxicity in induced pluripotent stem cells
Differentiated iPSCs were washed with 'oxidative stress medium' (same formula as DA2 medium, but with a B-27 supplement lacking antioxidants) (Life Technologies) and MGO was directly added to medium. Cells were incubated at 37 C for 18 h and cytotoxicity assessed by measuring the cell supernatant with the LDH cytotoxicity detection kit (Roche Applied Science). The samples were measured in triplicate on a PHERAstar FS plate reader (BMG Labtech).
Drosophila lines
Flies were raised at 25 C in LD12:12 on standard maize food. The elav-GAL4 (c155), w;UASeGFP; + (5431) and w; + ;UASaSyn (8146) transgenic lines were obtained from the Bloomington Stock Center (Bloomington, Indiana). RNAi transgenic lines were obtained from the Vienna Drosophila RNAi Center (VDRC). For Glo1 knockdown, the 101560 line from the KK Library (phiC31-based transgenes at a single, defined site) was used. For Tpi knockdown, two lines were used from the GD Library (P-element based, random insertion site): 25643 ( Fig. 2 ) and 25644 ( Supplementary Fig. 3 ).
Negative geotaxis and survival assays
Negative geotaxis assays were performed as described (Ali et al., 2011) . The same fly groups were tested at Days 10, 20 and 30 post-eclosion. For the survival assay, female flies of the desired genotype were collected and kept in groups of 10 in separate vials. Flies were passaged onto fresh food every 2-3 days and the number of dead individuals was scored.
Glycation studies in mice
Animal experiments were performed according to institutional and national regulations.
Brains from 4-(young) and 22-month-old (old) mice expressing human a-synuclein, were quickly removed and homogenized in RIPA buffer in the presence of protease and phosphatase inhibitors (Roche Complete and PhosStop). Brains from 2.5-(young), 11-and 17-month-old (old) wildtype mice were also processed.
Old male mice (6-7 months old) expressing human a-synuclein under the control of the Thy-1 promoter (a-synuclein transgenic) (Rockenstein et al., 2002) or B6D2F1 wild-type littermate controls received MGO, or vehicle (PBS, pH 7.4) injection under deep anaesthesia (80 mg/kg ketamine hydrochloride, 5 mg/kg xylasine hydrochloride). 2 Â 1 ml of MGO (340 mM) or PBS were injected into the substantia nigra (stereotactic coordinates: AP: 3.1; L: À1.2; DV: À4.2 from Bregma) or the striatum (stereotactic coordinates: AP: 0.86; L: À1.5; DV: 5/5.5 from dura) using glass microcapillary with a flow rate of 250 nl/min.
For immunohistochemistry, mice were transcardially perfused with 4% paraformaldehyde (PFA) 7 days post-injection. Brains were removed and post-fixed for 2 h at 4 C and then cryoprotected in TBS (pH 7.6) containing 30% sucrose (w/v) overnight at 4 C. Coronal free-floating sections (30 mm) were stained as reported previously (Szego et al., 2012) . Briefly, sections were incubated either with anti-tyrosine hydroxylase (TH) rabbit (Millipore, 1:1000), anti-CEL (Cosmobio, 1:1000), anti-aSyn (610786, 1:1000, BD Transduction laboratories), anti-phospho-synuclein (Ser129) (pSyn, Wako, 1:1000), anti-vesicular monoamine transporter (VMAT, 1:2000, Abcam), anti-NeuN mouse (Millipore, 1:1000) or anti-a-synuclein aggregation clone 5G4 (MABN389, 1:1000, Millipore) for 48 h at 4 C. Sections were then treated either with Alexa Fluor Õ -conjugated secondary antibody (1:1000, Invitrogen) or with biotinylated anti-mouse (NeuN) or antirabbit (TH) IgG (Vector Laboratories, 1:200) followed by avidin-biotin-horseradish peroxidase (HRP) complex (Vector Standard Elite Õ Kit, 1:500). Peroxidase labelling was visualized by diaminobenzidine tetrahydrochloride (DAB). Omission of the primary antibody resulted in no staining.
Numbers of TH-, VMAT-, DAPI-or NeuN-positive neurons were counted and estimated by using the optical dissector (StereoInvestigator; MBF Bioscience) (Szego et al., 2013) ; (100 Â objective, AxioImager M2; Zeiss; counting frame: 50 Â 50 mm, grid size: 200 Â 200 mm; every fourth section was analysed). Counts were performed manually and blinded for experimental grouping. Fluorescent images were taken using an Olympus IX-81 microscope (Olympus). Exposure time was equal for the same staining across the experimental groups. Fibre density in the striatum was analysed as previously described (Szego et al., 2012) .
For visualization of TH-positive fibres in the striatum, we used nickel intensification of the TH-staining (without Nissl counterstaining), as described previously (Szego et al., 2012) . Briefly, sections were treated with anti-TH (rabbit polyclonal, 1:1000, Millipore) antibody for 48 h at 4 C, then treated with biotinylated anti-rabbit IgG (1:200; Vector Laboratories) followed by avidin-biotin-horseradish peroxidase (HRP) complex (Vector Standard Elite Õ Kit, 1:500). Peroxidase labelling was visualized by diaminobenzidine tetrahydrochloride.
For protein analysis, brains were quickly removed, striatum dissected and samples homogenized in RIPA buffer in the presence of protease and phosphatase inhibitors (Roche Complete and PhosStop). Samples were then rotated for 1 h at 4 C and centrifuged at 18 000 g for 30 min. For further analyses, we used the soluble fractions. a-Synuclein was partially purified and enriched as described (Vicente Miranda et al., 2013) . For immunoblotting, we used anti aSyn (BD Transduction laboratories, S63320, 1:3000), anti-CEL (Cosmobio, CAC-AGE-M02, 1:500) or anti-AGEs (Millipore, AB9890, 1:1000).
Animals used for electrophysiological studies
Wild-type male Wistar rats (8-12 weeks old) were obtained from Harlan Interfauna Iberica, SL. All procedures used in the present study complied with the European Community guidelines (86/609/EEC) and Portuguese law on Animal Care (1005/ 92). Environmental conditions were kept constant: food and water ad libitum, 21 AE 0.5 C, 60 AE 10% relative humidity, 12 h light/dark cycles.
Hippocampal slice preparation
Animals were anaesthetized under halothane atmosphere and sacrificed by decapitation. Brains were rapidly removed and the hippocampi were dissected free in ice-cold artificial CSF composed of (in mM): 124 NaCl, 3 KCl, 1.25 NaH 2 PO4, 26 NaHCO 3 , 1 MgSO 4 , 2 CaCl 2 , and 10 D-glucose, previously gassed with 95% O 2 and 5% CO 2 , pH 7.4. Slices (400-mm thick) were cut transversally along the primary axis of the hippocampus with a McEwen tissue chopper and allowed to recover functionally and energetically for at least 60 min in a resting chamber immersed in the same solution, at room temperature (22-25 C) (Fredholm et al., 1984) . Slices were then incubated for 90 min either with vehicle, glycated a-synuclein (0.5 mM MGO for 30 h) or a-synuclein in gassed artificial CSF. The range of concentration chosen for a-synuclein incubation was based on previous data using 500 nM of different a-synuclein species (Diogenes et al., 2012) . All incubations were performed at room temperature to avoid neuronal damage by hypoxic injury (Schiff and Somjen, 1985) . After this preincubation period, one slice was carefully deposited in a recording chamber for submerged slices and continuously superfused with gassed artificial CSF at a constant flow (3 ml/min) and temperature (32 C).
Evoked field synaptic potential recordings
Evoked field synaptic potentials (fEPSPs) were recorded through an extracellular microelectrode filled with 4 M NaCl (2-4 M resistance) placed in the stratum radiatum of the CA1 area, as previously described (Diogenes et al., 2011) . The pathway of Schaffer collateral fibres was stimulated (rectangular pulses of 0.1 ms duration) once every 10 s by a bipolar wire electrode placed on the Schaffer fibres in the CA3 area. The initial intensity of the stimulus (200 mA) was adjusted to obtain a submaximal fEPSP slope with a minimum population spike contamination, near one-third of the fEPSP slope obtained with supramaximal stimulation. The averages of eight consecutive fEPSPs from the Schaffer collateral CA1 pathway were obtained and quantified as the slope of the initial phase of the potential. Recordings were obtained with an Axoclamp 2B amplifier (Molecular Devices), digitized and continuously stored on a personal computer with the WinLTP program (Anderson and Collingridge, 2001 ).
Long-term potentiation induction
Long-term potentiation (LTP) was induced after obtaining a stable recording of fEPSP (each fEPSP is the average of eight individual fEPSPs) slope in the Schaffer collateral pathway for at least 30 min. LTP was induced by a theta-burst protocol (10 trains separated by 200 ms, four pulses each, 100 Hz) in the Schaffer collaterals/CA1 synapse. The intensity of the stimulus was kept constant throughout these induction protocols. LTP was quantified as the percentage of change in the average slope of the fEPSP taken from 46 to 60 min after LTP induction in relation to the average slope of the fEPSP measured during the 10 min that have preceded the induction of LTP. 
Glycation studies in human tissue
Mass spectrometry analysis
Total protein extracts from Áglo1 yeast expressing a-synuclein, H4 cells expressing a-synuclein treated with MGO (0.5 mM) and brain samples from B6D2F1 wild-type mice or Wistar wild-type rat were processed (Vicente Miranda et al., 2013) . Mass spectrometry was carried out on an Applied Biosystems 4700 Proteomics Analyzer with TOF/TOF ion optics as previously described (Vicente Miranda et al., 2013) . All peptide mass values were considered monoisotopic, a mass spectrometry mass tolerance was set at 100 ppm. Trypsin and endoproteinase Glu-C were assigned as digestion enzymes of a-synuclein. A triple miscleavage was allowed and oxidation of methionyl residues, acetylation of the N-terminal region, and carboxyethylation (CEL) of lysine residues were assumed as variable modifications. All peaks with S/N 4 5 were included for matching against in silico digestion of corresponding a-synuclein sequence (Homo sapiens, Mus musculus or Rattus) in mMass software (Strohalm et al., 2010) .
a-Synuclein recombinant protein expression and purification
Escherichia coli BL21 (DE3) pLysS competent cells (Novagen) were transformed with human a-synuclein wild-type, A30P, A53T and E46K PT7-7 constructs. Expression and purification was performed as previously described (Vicente Miranda et al., 2013) 
Kinetics of a-synuclein fibril formation
Solutions of human recombinant a-synuclein (100 mM) were agitated at 37 C in the presence of MGO. Fibril formation was monitored with Thioflavin T (ThT) binding assay as previously described (Naiki et al., 1989 (Naiki et al., , 1990 . Fluorescence measurements were performed using a Perkin Elmer LS50B spectrofluorometer, in quartz cuvettes with 1 cm excitation light path. ThT fluorescence was recorded immediately after ThT binding from 470 to 600 nm with excitation at 450 nm, an increment of 0.5 nm, an integration time of 1 s and 5 nm slits for both excitation and emission. For each sample, the signal was obtained as the ThT intensity at 482 nm from which was subtracted a blank measurement recorded prior to the addition of a-synuclein to the ThT solution.
Secondary structure kinetic analysis by circular dichroism
Secondary structure analysis of MGO-incubated a-synuclein was performed by far-UV (185-260 nm) circular dichroism (CD) in a Jasco J810 spectropolarimeter equipped with a temperature control unit Julabo F25. Far-UV CD spectra were recorded in solutions of 100 mM a-synuclein in a 0.01 cm (linear) path length quartz cuvette at 37 C in 50 mM potassium phosphate buffer, pH 7.4, with 150 mM of NaF. For each spectrum, three scans were averaged.
a-Synuclein oligomer formation analysis by size exclusion chromatography
Oligomerization of human a-synuclein upon methylglyoxal glycation was monitored by size exclusion chromatography (SEC). Solutions of monomeric a-synuclein treated with vehicle (PBS) or MGO (5 mM) were incubated and agitated at 37 C. Samples (50 ml at 100 mM) were analysed by SEC at defined incubation times, after filtration with a 0.2 mm Whatman filter. SEC was performed with HPLC Jasco PU-2080 Plus isocratic pump with a UV detector Jasco 2075. The mobile phase was 50 mM PBS pH 7.4 with 150 mM NaF. Separation was achieved on a molecular exclusion analytical column (GE-Healthcare Superdex 75 10/300 GL) at a flow rate of 0.4 ml/min. Eluting peaks were monitored at 275 nm.
a-Synuclein oligomer formation analysis by dynamic light scattering
Oligomer formation was monitored by dynamic light scattering as previously described (Martins et al., 2008; Faustino et al., 2014) . Dynamic light scattering experiments performed on a Malvern Zetasizer Nano ZS with backscattering detection at 173
, equipped with a He-Ne laser ( = 632.8 nm), using glass cuvettes with round aperture at 25 C. Agitated a-synuclein (30 h at 900 rpm), treated with Tris-buffer or MGO (0.5 mM) was diluted to 7 mM in Tris-buffer. Samples were allowed to equilibrate for 15 min at 25 C before each 10 measurements set (each set is the average of 10 runs, with 10 s per run). Each experiment was repeated at least three times. Data were evaluated in Zetasizer Nano ZS software (Malvern).
Nuclear magnetic resonance spectroscopy
MGO-glycation of a-synuclein was obtained by incubating 50 mM of protein with 4.6 molar excess of MGO in 20 mM sodium phosphate buffer pH 7.5. After 2.5 days of reaction at 15 C, buffer was exchanged to HEPES 25 mM pH 7.0 NaCl 50 mM.
1 H 15 N HSQC spectra of wild-type and glycated 15 N-labelled a-synuclein samples were acquired at 15 C on a 600 MHz Bruker spectrometer, in HEPES 25 mM pH 7.0 NaCl 50 mM, 10% D 2 O. a-Synuclein backbone resonance assignment was transferred from previous studies (Bertoncini et al., 2005) . In case of glycated a-synuclein, peak centre was adjusted only in regions of small signal overlap. Peaks affected by severe overlap were excluded from the analysis. Nuclear magnetic resonance (NMR) data were processed and analysed with NMRPipe (Delaglio et al., 1995) and Sparky (T. D. Goddard and D. G. Kneller, University of California, San Francisco).
a-Synuclein binding studies to small unilamellar vesicles
Small unilamellar vesicles (SUVs) were prepared using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA) (Avanti Polar Lipids), at 1:1 molar ratio following the procedure described previously (Karpinar et al., 2009) . SUVs were prepared in HEPES 25 mM pH 7.0 NaCl 50 mM. Starting from 12.5 mM total lipid concentration, the SUVs, isolated after sonication and ultracentrifugation showed a hydrodynamic diameter of 25 AE 4 nm as determined by dynamic light scattering. Again, MGO-glycation of a-synuclein was obtained by incubating 50 mM of protein with 4.6 molar excess of MGO in 20 mM sodium phosphate buffer pH 7.5. After 2.5 days of reaction at 15 C, buffer was exchanged to HEPES 25 mM pH 7.0 NaCl 50 mM.
Far-UV CD spectra were recorded at 20 C using 1-mm length Hellma quartz cuvette in Chirascan (Applied Photophysics) spectrometer, with 0.5 nm bandwidth. Samples were measured at 7 mM protein concentration in 5 mM sodium phosphate buffer pH 7.0. To obtain the spectra of free and SUV-bound a-synuclein, measurements were done in triplicate and the contribution of buffer and vesicles to the CD signal was subtracted as appropriate.
Transmission electron microscopy
Aggregated a-synuclein (5 ml of 100 mM) treated with vehicle (PBS) or MGO (5 mM) was applied to carbon-coated Formvar 200 mesh grids (Electron Microscopy Sciences) and incubated at room temperature for 60 s. The grids were then washed sequentially by depositing 10 ml droplets of double distilled sterile water (twice) followed by a 10 ml droplet of fresh 2% (w/v) uranyl acetate, which remained on the grid for 30 s. After each step, the excess solution was blotted with Whatman Õ filter paper, and the grids were vacuum dried from the edges. The samples were analysed using a Phillips CM-10 TEM microscope operated at 100 kV acceleration voltage.
a-Synuclein clearance
For cycloheximide chase experiments, H4 cells were transfected as previously described (Vicente Miranda et al., 2013) with pSI-aSyn plasmid. After 24 h, cells were treated with vehicle (H 2 O) or MGO (0.5 mM) for 16 h. Media was renewed and cells rechallenged with vehicle or MGO for 24 h in the presence of cycloheximide (100 mM, added at given time points). Protein extracts were immunoblotted.
Proteasome impairment was assessed as the amount of unstable GFP (GFPu) accumulation. H4 cells were cotransfected with empty vector with GFPu; a-synuclein with GFPu or SynT with GFPu. Twenty-four hours post-transfection, media was renewed and cells treated with vehicle (H 2 O) or MGO (0.5 mM) for 16 h and processed for immunoblotting with anti-GFP antibody (NeuroMab, P42212).
For autophagy impairment studies, H4 cells were transfected with empty vector, with a-synuclein or co-transfected with SynT together with Synph 1. Twenty-four hours post-transfection, media was renewed and cells treated for 16 h with vehicle (H 2 O) or MGO (0.5 mM). Media was again renewed and cells were rechallenged with vehicle or MGO during autophagy blockage with ammonium chloride (20 mM) together with leupeptin (200 mM) for 2 h. Autophagy activity was measured as the amount of accumulated LC3-II after treatment with autophagy blockers as previously described (Macedo et al., 2015) . P62 basal levels were also assessed in cells treated with vehicle or MGO (0.5 mM) for 16 h. Then, the media was renewed and cells were treated again with vehicle or MGO for 4 h (SQSTM1 D-3, sc-28359, 1:3000).
For a-synuclein release studies, H4 cells, co-transfected with SynT and Synph 1 for 24 h were treated with MGO (0.5 mM) for 16 h. Media was renewed, and cells were again treated with MGO (0.5 mM) for 6 h, media collected, applied to a dot-blot system and immunoblotted with anti-a-synuclein by standard procedures.
In vitro ubiquitination assays
Recombinant a-synuclein was glycated in vitro as described above. Both glycated or non-glycated a-synuclein were incubated in a reaction mixture containing 40 mM Tris-HCl (pH 7.6), 5 mM MgCl 2 , 2 mM DTT, 1 mM ATP-g-S, 7.5 mg ubiquitin, 1 mM ubiquitin aldehyde, 100 ng E1 and 200 ng UbcH5b, in the presence or absence of 500 ng SIAH-2. Samples were incubated at 37 C for 1 h, and the reaction was stopped by the addition of SDS sample buffer. Samples were immunoblotted and mono-ubiquitinated a-synuclein determined using an antia-synuclein antibody.
MGO scavengers treatment in H4 cells
Twenty-four hours after SynT and Synph 1 co-transfection, cells seeded at 20 000 cells/cm 2 in 35 mm imaging dishes (Ibidi) or seeded at 30 000 cells/cm 2 in 6-well plates (TPP) were treated with vehicle (H 2 O), MGO (0.5 mM), aminoguanidine (100 or 250 mM), tenilsetam (100 or 250 mM) or cotreated with vehicle or MGO (0.5 mM) with aminoguanidine (250 mM) for 16 h. a-Synuclein clearance assays were also performed in the presence of aminoguanidine (250 mM) or tenilsetam (250 mM).
Treatment of Drosophila with aminoguanidine hydrochloride or tenilsetam
Aminoguanidine hydrochloride (SIGMA: 396494), dissolved in PBS, tenilsetam (Axon Medchem, Axon 1470) dissolved in dimethyl sulphoxide (DMSO), PBS or DMSO were added to standard maize media at the required doses (100 or 300 mM). Newly emerged flies were placed on the drug food and kept for 10 days changing them daily with freshly prepared food containing the compound. Climbing activity was assessed at Day 10.
Compliance with ethical standards
The human samples used in our study were obtained from the ADRC at MGH, Boston, so all ethical considerations were taken into account. Animal work was performed with the approval from the animal care committee of IMM, Lisbon, Portugal.
Results
MGO induces a-synuclein aggregation and toxicity in cell models of Parkinson's disease First, we investigated the effect of MGO on a-synuclein aggregation and toxicity in yeast cells constitutively expressing a-synuclein . We modulated MGO levels, using either increased amounts of D-glucose in the media, or genetically, using Glo1 (Áglo1) or triose phosphate isomerase (Tpi) deletion (Átpi) strains, conditions known to increase the levels of MGO and promote the formation of AGEs (Gomes et al., 2005; Guix et al., 2009; Orosz et al., 2009) . We found that these glycation-promoting conditions increase MGO levels $3-fold (Supplementary Fig. 1A ). Glycating conditions increased both the percentage of cells with a-synuclein inclusions (Fig. 1A) , and a-synuclein toxicity in Áglo1 and Átpi mutant cells expressing wild-type a-synuclein (Fig. 1B) . Similar results were obtained with the Parkinson's disease-associated a-synuclein familial mutants A53T or E46K ( Supplementary Fig. 1B and C) . The increased toxicity upon glucose treatment was further confirmed by assessing yeast viability, and we observed a reduction in the number of CFUs (Supplementary Fig. 1D ).
To further assess the effect of glycation on a-synuclein aggregation and toxicity, human H4 cells were co-transfected with an aggregation-prone variant of a-synuclein, known as SynT (full-length a-synuclein fused with the first 83 amino acids of GFP), together with synphilin-1 (Synph 1), an a-synuclein-interacting protein that potentiates a-synuclein aggregation (McLean et al., 2001 ). As we previously reported, this model facilitates the visualization of a-synuclein inclusions that, in contrast with the expression of unmodified a-synuclein, does not form inclusions (Klucken et al., 2012; Basso et al., 2013; Guerreiro et al., 2013; Lazaro et al., 2014) . We selected 0.5 mM MGO as the working concentration as it increased protein glycation without increasing overall cytotoxicity in naïve cells (Supplementary Fig. 2A-C) . We found that this concentration, widely used in various studies (Nass et al., 2014; Chang et al., 2016; Hansen et al., 2016) , increased the levels of MGO $1.4-fold (Supplementary Fig. 2D ). Treatment with MGO resulted in a striking increase in the percentage of cells with inclusions (from $51% to $85%). We also observed an increase in the number of inclusions per cell ($17% to $35% increase of cells displaying at least 10 inclusions, or $34% to $62% within cells with inclusions) (Fig. 1C) . Although MGO induced cytotoxicity in empty vector transfected cells, MGO increased a-synuclein toxicity (2.5-fold versus vehicle treated SynT + Synph 1) (Fig. 1D) , and induced both a-synuclein Triton TM X-100 insolubility (3-fold versus control) (Fig. 1E) , and the formation of high molecular weight species, as assessed in 5-30% sucrose gradients (Fig. 1F) . The combination of MGO treatment in a-synuclein-expressing cells elicited a significant increase in cytotoxicity, but each insult alone was also cytotoxic. Therefore, it remains to be investigated whether the combination of both insults represents a synergistic effect. We also assessed whether MGO induced a-synuclein glycation. For this, we immunoprecipitated a-synuclein from cells expressing a-synuclein or from cells co-expressing SynT and Synph 1 after treatment with MGO (0.5 mM). Remarkably, we observed an increase in the levels of glycated a-synuclein or SynT (Fig. 1G) . This was also observed in whole cell lysates, where the glycation levels of several proteins are increased upon treatment with MGO ( Supplementary Fig. 2E ), however, the levels of Synph 1 were not altered in glycating conditions ( Supplementary Fig. 2F ). were probed for a-synuclein. The ratio between soluble and insoluble fractions is presented as SynT insolubility (n = 4). (F) H4 cells, as in C, were treated with vehicle (Ctrl) or MGO (0.5 mM) for 16 h. Native protein extracts were separated in a sucrose gradient. Fractions were immunoblotted and probed for a-synuclein. (G) H4 cells were treated as in (C). Cells were lysed and immunoprecipitated (IP) with an antibody against a-synuclein. Whole cell lysates (WCL) were probed for a-synuclein and for the corresponding loading control (b-actin). Immunoprecipitated samples were probed for a-synuclein and AGEs. Blue and green arrows indicate a-synuclein and SynT, respectively (n = 3 times). (H) Patient-derived neuronal differentiated iPSCs from a family with a SNCA locus triplication (SNCA 3X), an age-matched healthy control (Ctrl) and an a-synuclein shRNA silenced cell line derived from the SNCA 3X (SNCA 3X KD) were treated with increasing concentrations of MGO (0-2 mM). MGO toxicity was measured by the activity of released LDH, normalized to total cell death (n = 3), and is displayed as per cent of cytotoxicity. (I) Protein extracts collected from iPSCs from Ctrl, SNCA 3X and SNCA 3X KD lines were immunoblotted with anti-a-synuclein and anti-tubulin antibodies. (J) Differentiated LUHMES cells, naive (Ctrl), stably expressing only GFP, or a-synuclein and GFP were treated with increasing concentrations of MGO (0-5 mM). MGO toxicity was assessed by the MTS assay (n = 3). (K) Cells stably expressing GFP or a-synuclein treated with vehicle (PBS) or 1.5 mM MGO were processed for immunocytochemistry (ICC) and stained for a-synuclein (white), Caspase 3 (red) and DNA (blue 
MGO induces a-synuclein toxicity in dopaminergic-neural induced pluripotent stem cells and dopaminergic-LUHMES cells
We next asked whether the correlation between a-synuclein expression and MGO-induced toxicity was conserved in human neurons. For this, we evaluated the effects of MGO in two different dopaminergic (DA) cell models: differentiated human DA-neural iPSCs and LUHMES. IPSCs, derived from dermal fibroblasts from a patient carrying a triplication of the SNCA locus and from an age-matched healthy relative (Byers et al., 2011) , were cultured and differentiated into DA neurons according to established protocols (Mak et al., 2012; Oliveira et al., 2015) . LUHMES cells transduced with lentiviruses encoding a-synuclein-IRES-GFP or IRES-GFP, were differentiated into TH-positive neurons (DA-LUHMES) (Scholz et al., 2011) . Both types of human cells were treated with increasing concentrations of MGO. We observed a dose-dependent increase in MGO toxicity in terminally differentiated iPSCs carrying the SNCA gene triplication (SNCA 3X) (Fig. 1H) (Byers et al., 2011) . To determine whether toxicity was indeed associated with the expression of a-synuclein, we knocked down a-synuclein using shRNA (SNCA 3X KD) as in (Oliveira et al., 2015) (Fig. 1I ). This reduced MGO-induced toxicity (Fig. 1H) , confirming the interplay between MGO and a-synuclein. Likewise, DA-LUHMES cells expressing a-synuclein were more sensitive to MGO compared both to GFP-expressing and to non-transduced cells (Fig. 1J) , as observed through the appearance of dystrophic processes (Fig. 1K) . Together, these results revealed a strong connection between increased levels of a-synuclein and glycating conditions.
Glycation decreases motor performance, lifespan and survival in Drosophila
We next asked whether MGO-induced a-synuclein toxicity affected motor performance. To address this, we used an established Drosophila model of Parkinson's disease based on the pan-neuronal expression of human a-synuclein via the GAL4/UAS system (Feany and Bender, 2000) and interrogated whether genetic modulation of glycation, via knockdown of Glo1 or Tpi, altered a-synuclein-induced defects. We previously observed that knockdown of Glo1 or Tpi increases the overall levels of glycation (Vicente Miranda et al., 2016b), a phenotype that was also confirmed in this study ( Fig. 2A) . Importantly, we observed that knockdown of Glo1 or Tpi alone did not elicit neurodegeneration, as assessed by counting the number of rabdomeres (photoreceptors) (Vicente Miranda et al., 2016b) . Here, we observed that a-synuclein expression significantly impaired motor performance (measured as climbing ability, due to negative geotaxis) of the flies and, importantly, when a-synuclein was expressed in the RNAi lines, the climbing impairment was aggravated (Fig. 2B, C and Supplementary Fig. 3A ). Nevertheless, Tpi or Glo1 knockdown also elicited a climbing impairment per se.
In addition, the maximal lifespan in Glo1 knockdown reduced 2 days (comparing to non-silenced a-synuclein expressing flies) (Fig. 2D) . Although silencing of Tpi shortened the lifespan by 4 days in both wild-type flies and a-synuclein expressing flies (Fig. 2E) , we observed a striking decrease in survival starting 6 days post-eclosion (by Day 13, 77 AE 4% versus 93 AE 3%) survival for a-synuclein expressing flies (Fig. 2E and Supplementary Fig. 3B ).
Glycation induces neuronal loss in a mouse model of Parkinson's disease and impairs synaptic transmission in brain slices
Next, to determine whether glycation modulates a-synuclein toxicity in the brain in vivo, we evaluated the effects of MGO in transgenic mice expressing human a-synuclein under the control of the Thy1 promoter. We injected MGO and PBS in the two hemispheres (in the substantia nigra or striatum) of a-synuclein transgenic or wild-type control mice. Immunohistochemical analyses revealed a marked decrease in the number of TH-positive neurons in the MGOinjected side of the a-synuclein transgenic mice, when compared to the PBS-injected side (Fig. 3A) . Neuritic degeneration was also evident in the striatum, where the terminals of the nigral TH-positive neurons are located (Fig. 3A) . Remarkably, we detected high levels of CEL immunoreactivity only in the MGO-injected substantia nigra of a-synuclein transgenic mice, but not in the MGO-injected wildtype control substantia nigra (Fig. 3B) . Stereology analyses showed that injection of MGO induced a 32.9 AE 3.5% loss of TH-positive neurons, a 46 AE 5.1% loss of VMAT-, and a 43.0 AE 3.0% loss of DAPI-positive neurons (as a percentage of the PBS-injected side, compared to 9.6 AE 5.7; 9.7 AE 3.4, and 5.8 AE 7.4% loss of TH-, VMAT-or DAPI-positive neurons in wild-type mice, respectively) (Fig. 3C) . We should highlight that the results shown do not simply correspond to the total number of labelled neurons (TH, VMAT or DAPI), but to the percentage of neurons normalized to the corresponding control (MGO/PBS in wild-type mice, black bars; or MGO/PBS in a-synuclein transgenic mice, green bars in Fig. 3C ). Immunostaining for TH in coronal sections (revealed with DAB) confirmed that TH-positive neuronal loss was specifically observed in asynuclein transgenic mice injected with MGO ( Supplementary Fig. 4A ). When MGO was injected in the striatum, we also found a significant loss of NeuN-positive neurons in a-synuclein transgenic animals (13.5 AE 3.9%), while wild-type animals were almost unaffected (3.7 AE 1.7%) (Supplementary Fig. 4B ). In addition, striatal TH fibre density was reduced in both the a-synuclein transgenic and wild-type control animals, but was much more pronounced in a-synuclein transgenic mice (18.6 AE 4.1 versus 7.1 AE 2.2%) (Supplementary Fig. 4B ).
To establish whether MGO also promoted a-synuclein glycation, we enriched a-synuclein from striatal-injected extracts (Vicente Miranda et al., 2013) and measured the levels of CEL, the AGE derived from the reaction of MGO with lysine residues of proteins (Ahmed et al., 1997) , on a-synuclein. Since we showed by immunoprecipitation that a-synuclein was glycated and that glycated a-synuclein migrated with an identical molecular weight to that of a-synuclein (Fig. 1G) , we assumed that the CEL protein band overlapping with a-synuclein, corresponded to glycated a-synuclein. Upon quantification, we found that a-synuclein glycation increased $2-fold in MGO-injected a-synuclein transgenic animals (Fig. 3D) .
Interestingly, we found high reactivity against aggregated a-synuclein in the substantia nigra of the MGO-injected a-synuclein transgenic mice (Fig. 3E) . By analysing higher magnifications of substantia nigra sections, we observed aggregated a-synuclein both in cell bodies and neuronal processes ( Supplementary Fig. 5A ). In addition, we found stronger staining against phosphorylated a-synuclein (serine 129 phosphorylation, pS129) in the substantia nigra of MGO-injected a-synuclein transgenic mice ( Supplementary  Fig. 5B ) indicating increased a-synuclein pathology. pS129 signal was specifically present in surviving TH-positive neurons in MGO-injected a-synuclein transgenic mice as well ( Supplementary Fig. 5C ).
Immunohistochemistry for a-synuclein in mice injected in the striatum revealed presynaptic staining for both wildtype and a-synuclein transgenic mice. However, in a-synuclein transgenic mice treated with MGO, a-synuclein was also found in cell bodies. Importantly, staining with methoxy-XO4 (MX), an amyloid-binding dye (Klunk et al., 2002) , revealed amyloid-like inclusions adjacent to the MGO injection site in the a-synuclein transgenic mice ( Supplementary Fig. 5D ).
To assess whether glycation induced functional alterations on synaptic transmission, we used a paradigm based on the treatment of hippocampal brain slices with a-synuclein oligomeric species (Diogenes et al., 2012) . We found that a-synuclein that was previously glycated with MGO strongly impaired synaptic plasticity in the rat hippocampus (LTP aSyn 47 AE 3%; LTP aSyn-MGO 22 AE 4%) (Fig. 3F-I ). Importantly, PBS or MGO (35 mM) treatment did not affect LTP (Supplementary Fig. 6 ). To assess the relevance of a-synuclein glycation in Parkinson's disease and other synucleinopathies further, we analysed the glycation pattern of a-synuclein in extracts from the cortex from human brain tissue enriched for a-synuclein (Vicente Miranda et al., 2013) . Using the previous assumption, we observed that samples derived from both control individuals, without overt symptoms of neurological disorders, and from individuals diagnosed with Parkinson's disease or Lewy body dementia, showed reactivity for CEL. Strikingly, a-synuclein was also reactive for this modification (Fig. 3J) .
To establish whether this modification varied with ageing, as we predicted, we analysed brain samples from wild-type mice or human a-synuclein BAC transgenic mice at different ages. In transgenic mice, the expression of human a-synuclein is controlled by the human promoter, thereby avoiding possible confounding issues associated with a-synuclein overexpression. Importantly, we observed that a-synuclein was reactive for CEL (overlapping signal), and that this reactivity increased with age in both wild-type ($1.3-fold increase in old versus young animals) and asynuclein BAC transgenic mice (2.3-fold increase in old versus young animals) (Fig. 3K and L) .
Glycation occurs mainly in the N-terminal region of a-synuclein
Given that a-synuclein was found to be glycated in human brain and in mouse models, we sought to identify where glycation occurred in a-synuclein. For this, we used a proteomic approach (Vicente Miranda et al., 2013) . Briefly, we used mass spectrometry to analyse a-synucleinenriched protein extracts from yeast Áglo1 cells expressing human a-synuclein, from human H4 cells expressing human a-synuclein treated with 0.5 mM MGO, and from mouse and rat brain tissues. By matching the mass spectrometry data with the m/z ratios calculated from in silico digested a-synuclein sequences (including CEL as variable post-translational modification), we found that a-synuclein was mainly glycated in the N-terminal region (K6, K10, K12, K21, K23, K32, K34 and K43 and K45) in all samples analysed (Fig. 3M, Supplementary Fig. 7 and Supplementary Tables 1-16 ), hinting at possible effects on membrane binding and aggregation.
MGO promotes a-synuclein oligomerization and impairs lipid binding ability MGO glycation was previously shown to interfere with amyloidogenesis by stabilizing intermediate species (Lee et al., 2009; Oliveira et al., 2011; Padmaraju et al., 2011) . Thus, we investigated whether MGO affected the aggregation of wild-type and of three mutant variants associated with familial Parkinson's disease (A30P, E46K, and A53T). In agreement with our previous findings (Oliveira et al., 2011 , we found that, although glycation decreased a-synuclein fibril formation in vitro ( Fig. 4A and Supplementary Fig. 8A-C) , it potentiated the formation of a-synuclein oligomeric species, as observed by size exclusion chromatography analyses of MGO-treated versus non-treated a-synuclein (30 h of fibrillization). We found that oligomeric a-synuclein species were only present in samples with MGO (elution at 28 and 18 min) (Fig. 4B-D and Supplementary Fig. 8D ). Consistently, analysis of the particle size distribution by dynamic light scattering, revealed a more heterogeneous size distribution of glycated a-synuclein, with a significant increase in particles with a hydrodynamic diameter above 2300 nm ( Fig. 4C and D) . Moreover, using transmission electron microscopy, we observed that vehicletreated a-synuclein formed typical amyloid fibrils, whereas glycated a-synuclein formed amorphous aggregates and ringshaped particles (Fig. 4E) , consistent with a-synuclein oligomers (Lashuel et al., 2002a, b) .
To assess the effects of glycation on the structure of a-synuclein, we performed NMR analyses. We found that glycation induced a 76% reduction of the NMR backbone 1 H 15 N signals up to residue 64, demonstrating the N-terminal region of a-synuclein was the most affected ( Fig. 4F  and G) . The N-terminal domain of a-synuclein is involved in lipid-binding (Jo et al., 2000) . Interestingly, we observed that glycation impaired the typical transition between Figure 3 Continued followed by the presynaptic volley and the fEPSP. (H) Changes in fEPSP slope induced by y-burst stimulation were recorded from the CA1 region of hippocampal slices pretreated with a-synuclein or with glycated a-synuclein (aSyn-MGO) (a-synuclein 47 AE 3%, n = 4; aSyn-MGO 22 AE 4%, n = 4). (I) Bar graph of the LTP magnitude (change in fEPSP slope at 50-60 min) in relation to pre-y-burst values (100%) from experiments shown in H as indicated below each column (n = 4). Thermo-enriched brain samples from Parkinson's disease, Lewy body disease (LBD), or from control (C) individuals (J), or from young or old wild-type (K) or a-synuclein-transgenic mice (L) were probed with anti-CEL (red) and anti-a-synuclein (green). Arrows indicate a-synuclein molecular weight. The ratio between CEL and a-synuclein is shown as the CEL/a-synuclein ratio in young versus old mice. (M) Detection of lysine glycation sites in a-synuclein by peptide mass fingerprinting analysis of a-synuclein protein in total lysates from Thy1-a-synuclein transgenic mouse brain. The spectrum shows glycated a-synuclein peptides in red and other a-synuclein peptides in blue. Corresponding peptide sequences are illustrated (residues in red are glycated). For C and D, data are presented as average AE SD. For C, D, I, K and L, * P 5 0.05, ** P 5 0.01, *** P 5 0.001. For C, two-way ANOVA, followed by Tukey's multiple comparisons test. For D, one-way ANOVA, followed by Tukey's multiple comparisons test. Data in H and I are mean AE SEM. For H and I, one-way ANOVA test, followed by a Bonferroni's multiple comparison post hoc test. For K and L, unpaired t-test with equal SD. PD = Parkinson's disease.
random-coil and a-helical structure, which occurs when asynuclein binds to SUVs (Fig. 4H ).
Glycation blocks a-synuclein ubiquitination and impairs its clearance and release
As described above, we found that a-synuclein was glycated in the N-terminal region (Fig. 3M, Supplementary Fig. 7 and Supplementary Tables 1-16 ). Interestingly, several of those lysine residues are also known a-synuclein ubiquitination sites (Nonaka et al., 2005; Anderson et al., 2006) . We hypothesized that if a-synuclein is glycated this might impair its normal ubiquitination and clearance. To investigate the mechanism through which MGO glycation potentiated asynuclein-associated pathologies, we used a human cell model of a-synuclein aggregation (H4 cells, SynT-Synph 1 model). Strikingly, while we observed several ubiquitin and a-synuclein-positive inclusions in vehicle treated cells (as in Lewy bodies), no co-staining was observed in MGO-treated cells (Fig. 5A ). To confirm that glycation competed ubiquitination, we performed an in vitro assay using SIAH-2, an E3 ubiquitin ligase known to ubiquitinate a-synuclein. We observed that mono-ubiquitination of a-synuclein was reduced from 43 to 13% (Fig. 5B) .
Next, we followed the clearance of a-synuclein in cells upon blocking de novo protein synthesis with cycloheximide. Importantly, we found that MGO treatment reduced a-synuclein clearance (Fig. 5C ). To further dissect the effects of glycation on a-synuclein clearance, we investigated the activity of known a-synuclein clearance pathways (EbrahimiFakhari et al., 2012) . First, to assess the effects on the ubiquitin proteasome system (UPS), we used an unstable version of GFP (GFPu) that reports on the overall activity of the UPS (Bence et al., 2001) . In control cells, no accumulation of GFP was observed. Upon a-synuclein expression, GFP accumulated in both vehicle and MGO-treated cells but the levels were $2.5-fold higher in MGO versus PBS-treated cells (Fig. 5D) . Together, our data indicate that UPS impairment is potentiated when a-synuclein is glycated.
Second, to study the effect of glycation on the autophagylysosome pathway, we treated cells with a combination of ammonium chloride (NH 4 Cl) and leupeptin, known blockers of autophagy, according to established guidelines (Klionsky et al., 2016) . We observed that MGO severely decreased LC3-II levels in either a-synuclein or SynT expressing cells ($90% decrease) (Fig. 5E) . Consistently, we found that the basal levels of P62 were increased (Supplementary Fig. 9A ). These data indicate that glycation impairs the autophagy-lysosome pathway.
Finally, as a-synuclein can be released from cells (Marques and Outeiro, 2012) , we assessed whether this could also be affected by glycation. Interestingly, we found a significant reduction in a-synuclein release in cells treated with MGO ($50% decrease), therefore contributing to the intracellular accumulation of a-synuclein (Fig. 5F ).
MGO scavengers correct the clearance of a-synuclein, reduce aggregation and toxicity, and alleviate motor phenotypes in Drosophila Anti-MGO drugs such as aminoguanidine and tenilsetam are known scavengers of MGO (Webster et al., 2005) . Thus, we asked whether MGO scavenging could interfere with a-synuclein aggregation and toxicity. Importantly, both MGO scavengers reduced the intracellular levels of MGO by $20% (Fig. 6A ), resulting in a decrease of a-synuclein aggregation and toxicity by 20 and 50%, respectively (Fig. 6B and C) . In addition, treatment with either aminoguanidine or tenilsetam reverted the impairment of a-synuclein clearance upon glycation ( Fig. 6D and Supplementary Fig. 9B ).
To assess the therapeutic potential of aminoguanidine and tenilsetam further, we tested their effect in vivo, using Drosophila. Strikingly, treatment with aminoguanidine or tenilsetam for 10 days improved the motor performance of a-synuclein expressing flies in a dose-dependent manner. Treatment with aminoguanidine resulted in an improvement from 15 AE 1%, to 30 AE 2% with 100 mM, and to 37 AE 2% with 300 mM (Fig. 6E) . With tenilsetam, we observed an improvement from 34 AE 1% to 48 AE 2% with 100 mM, and to 54 AE 2% with 300 mM (Fig. 6F) .
Discussion
At present, the understanding of the molecular mechanisms underlying neurodegeneration in Parkinson's disease and other synucleinopathies is still limited. In particular, the age-dependency of most neurodegenerative disorders is t-test with equal SD; for B and C, ordinary one-way ANOVA, followed by Dunnett's multiple comparisons test; for D, two-way ANOVA, followed by Tukey's multiple comparison test; for E and F, ordinary one-way ANOVA, followed by Newman-Keuls multiple comparisons test.
intriguing, suggesting common factors may play important roles in both processes. While a-synuclein misfolding and accumulation is a major pathological hallmark in synucleinopathies, a-synuclein mutations occur only in a small fraction of all Parkinson's disease cases. Thus, it is logical to think that non-genetic factors, such as post-translational modifications (PTMs), might modulate the aggregation and toxicity of a-synuclein, as this is common among idiopathic and familial forms of synucleinopathies. Indeed, phosphorylation on S129 and in other sites has been extensively studied and found to modulate a-synuclein aggregation and toxicity in various model systems (Wang et al., 2012; Tenreiro et al., 2014a) . However, during the normal lifetime of a-synuclein, several other PTMs are likely to occur, thereby modulating its normal behaviour (Oueslati et al., 2010; Gonçalves et al., 2012; Beyer and Ariza, 2013) . In this context, we propose that particular PTMs may act as 'second-hits' that induce structural and stability alterations, thereby potentiating a-synuclein aggregation and toxicity. Although diabetes has been extensively linked to neurodegenerative diseases (Hu et al., 2007; Sun et al., 2012; Crane et al., 2013; Vagelatos and Eslick, 2013; Vicente Miranda et al., 2016a) , the molecular basis for this connection remains unclear. A known consequence of increased glucose levels is the, unavoidable, age-associated modification of specific amino acid residues in proteins in a process known as glycation, altering protein structure and function (Vicente Miranda and Outeiro, 2010) . Importantly, we recently found that glycation potentiates neurodegeneration in models of Huntington's disease (Vicente Miranda et al., 2016b) , further suggesting an association between hyperglycaemia and neurodegeneration. Strikingly, a recent clinical trial revealed that a drug used to treat diabetes resulted in improvements in both motor and cognitive metrics in Parkinson's disease subjects (Aviles-Olmos et al., 2013) . Here, we demonstrated that glycation, a direct consequence of diabetes, might play an important and underappreciated role in Parkinson's disease and other synucleinopathies by modulating a-synuclein biology (Fig. 7) .
Exploiting a yeast model of a-synuclein-mediated cellular pathologies, we found that glycation exacerbates a-synuclein toxicity and aggregation, and we then showed this effect was conserved in human cell lines and, importantly, in differentiated patient-derived iPSCs. Interestingly, upon knockdown of a-synuclein in iPSCs, the cytotoxicity of MGO is abolished, confirming that cytotoxicity is associated with the levels of a-synuclein.
Next, we evaluated the effects of glycation in animal models of Parkinson's disease. Remarkably, by promoting a-synuclein glycation through genetic or pharmacological manipulation of MGO levels, we recapitulated several pathological alterations in both a-synuclein transgenic Drosophila and mice. Glycation not only reduces the motor performance of a-synuclein expressing flies, but also decreases survival. In a-synuclein expressing mice, MGO injection in the substantia nigra causes an impressive loss of neuronal cells, including TH-positive neurons. Neuritic degeneration extended to the striatum, a region innervated by dopaminergic neurons from the substantia nigra. We also found extensive labelling for aggregated a-synuclein in the substantia nigra pars comapacta and of pS129 a-synuclein, confirming that glycation induces the aggregation of a-synuclein and leads to the accumulation of pathological a-synuclein.
To establish that a-synuclein glycation can indeed affect neuronal function, we used a functional paradigm that enables us to assess the effects of a-synuclein on synaptic transmission. As an experimental paradigm, we used rat hippocampal brain slices (Diogenes et al., 2012) . Indeed, we found that glycated a-synuclein impairs hippocampal long-term potentiation.
The concentrations of MGO used in our study are within, or below, the range used in other studies, and resulted in an increase in the levels of intracellular MGO ($36%). Importantly, our findings are strongly supported by genetic manipulations in yeast and flies and, therefore, constitute proof-of-concept that glycation of a-synuclein exacerbates its aggregation and toxicity. Strikingly, we demonstrate that glycated a-synuclein is present in aged human brains. Given the low number of available human brain samples, and the fact that all samples were derived from elderly individuals (473 years old), we could not establish whether the levels of CEL-glycated a-synuclein were higher in disease versus control brains. Thus, future studies with larger numbers of human brain samples should enable additional confirmation. Nevertheless, using brain tissue from wild-type or human a-synuclein BAC transgenic mice (expressed under the regulation of the human a-synuclein promoter), we observed that the levels of glycated a-synuclein increase with age. These findings strongly support our hypothesis that glycation might be associated with synucleinopathies in an age-dependent manner.
Our in vitro studies provide valuable mechanistic insight into the effects glycation has on a-synuclein. We found it increases a-synuclein oligomerization and interferes with the N-terminal structure of the protein, reducing the ability of a-synuclein to bind to lipid membranes. Together, these findings confirm that glycation may perturb the physiological role of a-synuclein on vesicular trafficking (Nemani et al., 2010; Scott et al., 2010) .
Given that CEL-glycation occurs specifically in lysine residues, we asked whether it affected a-synuclein ubiquitination and clearance. Our findings confirm our hypothesis, and demonstrate that MGO-treatment, reduced a-synuclein ubiquitination, reduced UPS-(in the a-synuclein aggregation model) and autophagy-lysosome pathway-mediated degradation of a-synuclein, and also the release of a-synuclein from cells. It is possible that the proteasome dysregulation induced by a-synuclein in the conditions tested saturates the system, limiting the ability to detect an additional accumulation of GFPu under glycation conditions. Overall, the failure in these proteostasis components contributes to the accumulation, aggregation and cytotoxicity of a-synuclein.
Finally, we sought to demonstrate the potential value of pharmacological modulation of glycation in models of synucleinopathy. Using anti-glycation agents, we could attenuate or revert the phenotypes observed. Remarkably, we demonstrate that anti-MGO treatment improves motor performance in vivo in a-synuclein-expressing flies, and reduces both a-synuclein aggregation and toxicity in cultured cells by restoring a-synuclein clearance.
Generally, glycation is responsible for increasing oxidative stress and inflammation via activation of the receptor for AGE (RAGE) (Bierhaus et al., 2001; Vicente Miranda and Outeiro, 2010) . Thus, our findings are in line with previous studies reporting elevated RAGE levels in Parkinson's disease tissue (Dalfo et al., 2005) . As RAGE ablation was shown to protect against MPTP/MPP + -induced dopaminergic cell loss (Teismann et al., 2012) , we hypothesize that strategies aimed at blocking RAGE might prove valuable in Parkinson's disease. Our findings further support the hypothesis that hyperglycaemia, which directly correlates with increased levels of MGO, might play an unanticipated role in the molecular basis of Parkinson's disease and other synucleinopathies through the modulation of a-synuclein aggregation, accumulation, and toxicity. This is strongly supported by the fact that diabetes is considered a risk factor for Parkinson's disease (Vicente Miranda et al., 2016a) . Importantly, a direct genetic association between glycation and Parkinson's disease is already known, although it has not been explored. This link comes from the fact that mutations in DJ-1 (PARK7), a protein recently shown to be an anti-MGO enzyme with glyoxalase and deglycase activities ( 2015), are associated with recessive forms of Parkinson's disease. Importantly, DJ-1 restores the activity of several glycated proteins, including glyceraldehyde-3-phosphate dehydrogenase, aldolase and aspartate aminotransferase. Thus, Parkinson's disease cases associated with DJ-1 mutations might result from excessive protein glycation. Consistently, we already established a physical interaction between DJ-1 and a-synuclein, and showed that human wild-type DJ-1 as well as yeast DJ-1 orthologues, protect against a-synuclein toxicity (Zondler et al., 2014) . In our view, this constitutes an important link that is only now beginning to be appreciated, and suggests that the modulation of anti-glycation enzymes, such as DJ-1 or GLO1 (as we demonstrate in the present study), or the direct manipulation of MGO levels using scavengers, constitute novel and attractive strategies for therapeutic intervention in synucleinopathies.
Altogether, our study suggests that glycation may constitute a missing link in our understanding of the molecular pathogenesis of Parkinson's disease and other synucleinopathies, acting as a 'second hit' that increases the risk for disease onset, at least in a significant subset of synucleinopathy patients.
